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The concurrent expression of MYC and BCL2 on immunohisto-
chemistry (IHC) ('double expressor') is recently emerging as one of
the strongest and most unfavorable prognostic factor for diffuse
large B-cell lymphoma (DLBCL).1–5 Nevertheless, the higher
prevalence of older patients, together with the association
between double expressor DLBCL and advanced age, may have
represented a potential confounding factor affecting the conclu-
sions of all these studies. In fact, older DLBCL patients generally
have inferior outcome due to the higher risk of adverse events
and difﬁculties to perform high-dose salvage therapies.6 This
potential age bias was strongly suggested by a recent German
study that included only young DLBCL patients at diagnosis, and
did not conﬁrm the negative prognostic effect of the double
expressor phenotype after either eight cycles R-CHOEP-14 or
sequential high-dose therapy followed by autologous stem cell
transplant (ASCT).7 This discordant result may be explained by
either the lower prognostic relevance of MYC/BCL2 among young
DLBCL patients, and by the ability of intense chemotherapy
regimens to overcome the negative prognostic value of MYC/BCL2
co-expression. In order to investigate these hypotheses, we
analyzed the MYC and BCL2 co-expression clinical impact on a
consecutive series of 140 DLBCL patients, 71 at diagnosis and 69
at ﬁrst relapse, respectively. All patients were treated with intense
chemotherapy programs oriented to ﬁnal ASCT consolidation
between 2003 and 2015 at the Istituto Nazionale dei Tumori
Milano. Seventy-one naïve DLBCL patients (51%) were treated in
ﬁrst line with high-dose sequential chemotherapy integrated with
monoclonal antibody Rituximab (R-HDS; Supplementary
Figure S1).8,9 Eligibility to this intense approach was decided
considering either the high international prognostic index (IPI)
score or the extended nodal and extranodal disease. The second
cohort was composed by 69 (49%) DLBCL patients in ﬁrst relapse
after chemo-immunotherapy regimens and treated with intense
salvage programs, including 53 (77%) treated with R-HDS and 16
(23%) with CORAL-like treatment (R-ICE/R-DHAP as induction
chemotherapy before transplant), respectively.10 The patients’
median age was 60 years (range, 30–76); 48 patients (34%) were
older than 60 years, but all were considered ﬁt and eligible for
intense chemotherapy and transplant consolidation. The median
follow-up of the whole series was 83 months (range 2–200). All
pathological revisions and IHC colorations were performed as
described in Supplementary Material and Methods and
Supplementary Table S1.11 All statistical analyses were performed
using appropriate scripts in R software (www.r-project.org;
Supplementary Material and Methods).
Among the whole cohort of patients, 78 (55.7%) and 65 (46.4%)
patients were characterized by BCL2 and MYC positivity on IHC,
respectively; 38 (27.1%) were classiﬁed as double expressor DLBCL.
In order to detect the real 'double hit' DLBCL patients, FISH
analysis was performed only on 52/65 (80%) MYC IHC-positive
patients. MYC rearrangements was detected in 8/52 (15%)
patients and among them only one also harbored a BCL2
rearrangement, being classiﬁed as 'double hit' DLBCL.1–5,12 Except
for a slightly higher prevalence of patients with Eastern
Cooperative Oncology Group (ECOG) score ⩾ 2 among non-
double expressor patients, no other signiﬁcant clinical differences
were observed between two groups (Table 1). The overall
response rate to high-dose therapy was 67% (n= 94), and 59%
(n= 82) of all patients were transplanted according with treatment
program. Sixty-eight (82%) of these were in CR at the time of
transplant. Fifty-eight (41%) patients were not able to receive
planned ASCT for refractory disease (n= 47, 33%), poor mobiliza-
tion (n= 3; 2%), concurrent infections and/or toxic complications
(n= 7; 4.3%) or patient’s preference (n= 1; 0.7%). Double expressor
patients did not show any higher prevalence among patients that
were not transplanted considering either all patients and naive
and relapsed series separately (Table 1). Myeloablative condition-
ing regimens were high-dose chemotherapy schedules in 63
patients (77%) and high-dose 90Y-Ibritumomab Tiuxetan in 19
(23%), respectively.13 Except for older age and ECOG score ⩾ 2, no
clinical and outcome differences were observed between the two
groups (Supplementary Table S2).
The overall 5-year event free survival (EFS) and overall survival
(OS) were 47.2% (95% CI, 42.8–51.6%) and 63.9% (95% CI, 59.5–
68.3%) respectively. In the whole cohort, double expressor
patients showed a similar 5-year EFS (42.4% (95% CI, 34–50.8%)
vs 49.1 (95% CI, 44–54.2%)) and OS (55.9% (95% CI, 46.7–65.1%) vs
66.4% (95% CI, 64.4–71.4%)) to other patients (Figures 1a and b).
Focusing on patients older than 60 years, MYC/BCL2 co-expression
did not affect EFS or OS (data not shown).
In the 71 naïve DLBCL, the 5-year EFS and OS were 65.2% (CI
95%, 59.4–71%) and 83.5% (CI 95%, 78.7–88.3%), respectively. IPI
score42 and ECOG score ⩾ 2 were associated with higher risk of
relapse and shorter EFS (Po0.0001 and P= 0.05, respectively). OS
was only inﬂuenced by ECOG score ⩾ 2 (P= 0.04). MYC and BCL2
aberrant expression was observed on IHC in 31 (43.6%) and 37
(52.1%) patients, respectively. Among them, 20 (28%) were
characterized by BCL2 and MYC co-expression. Hans COO
classiﬁcation, Ki-67 expression, single MYC and BCL2 expression
were not associated with inferior outcome. Conversely, the co-
expression of MYC/BCL2 was associated with a trend towards
worse 5-year EFS compared with the other patients in the cohort
(49.4% (95% CI, 37.7–61.5%) vs 71.5% (95% CI, 65–78%); P= 0.06)
(Figure 1c). However, this higher relapse risk did not affect ﬁnal
5-year OS (76.7 (95% CI, 66.4–87) vs 83.4 (78–88.8)) (Figure 1d). By
multivariate analysis, only the MYC/BCL2 co-expression retained
its independent prognostic power for EFS but not for OS
(Supplementary Table S3).
The second study cohort included 69 DLBCL patients in ﬁrst
relapse after rituximab containing regimens (R-CHOP 53 (77%) and
other regimens 16 (23%)). Thirty (43%) patients responded to
Citation: Blood Cancer Journal (2016) 6, e491; doi:10.1038/bcj.2016.99
www.nature.com/bcj
Ta
bl
e
1.
M
ai
n
cl
in
ic
al
fe
at
u
re
s
an
d
tr
ea
tm
en
t
va
ri
ab
le
s
o
f
al
l
D
LB
C
L
tr
ea
te
d
w
it
h
in
te
n
se
ch
em
o
-im
m
u
n
o
th
er
ap
y
p
ro
g
ra
m
w
it
h
ﬁ
n
al
A
SC
T
co
n
so
lid
at
io
n
A
ll
D
LB
CL
pa
tie
nt
s
N
aï
ve
D
LB
CL
Re
la
ps
ed
D
LB
CL
Al
l
D
ou
bl
e
ex
p
N
ot
do
ub
le
ex
p
P-
va
lu
e
Al
l
na
ïv
e
pt
s
N
aï
ve
do
ub
le
ex
p
N
aï
ve
no
t
do
ub
le
ex
p
P-
va
lu
e
A
ll
re
la
ps
ed
pt
s
(6
9)
Re
la
ps
ed
do
ub
le
ex
p
Re
la
ps
ed
no
t
do
ub
le
ex
p
P-
va
lu
e
M
al
e
84
/1
40
(6
0%
)
26
/3
8
(6
8.
4%
)
58
/1
02
(5
7%
)
N
S
39
/7
1
(5
4.
9%
)
13
/2
0
(6
5%
)
26
/5
1
(5
1%
)
N
S
45
/6
9
(6
5.
2%
)
13
/1
8
(7
2.
2%
)
32
/5
1
(6
2.
7%
)
N
S
A
n
n
A
rb
o
r
st
ag
e4
2
11
0/
13
8
(8
0%
)
26
/3
7
(7
0%
)
84
/1
01
(8
3%
)
N
S
65
/7
1
(9
1.
5%
)
19
/2
0
(9
5%
)
46
/5
1
(9
0%
)
N
S
45
/6
7
(6
7.
1%
)
7/
17
(4
1.
1%
)
38
/5
0
(7
6%
)
N
S
A
g
e4
60
48
/1
40
(3
4%
)
10
/3
8
(2
6%
)
38
/1
02
(3
7%
)
N
S
24
/7
1
(3
3.
8%
)
5/
20
(2
5%
)
19
/5
1
(3
7%
)
N
S
24
/6
9
(3
4.
7%
)
5/
18
(2
7.
7%
)
19
/5
1
(3
7.
2%
)
0.
01
EC
O
G
⩾
2
26
/1
40
(1
8.
5%
)
3/
38
(8
%
)
23
/1
02
(2
3%
)
0.
05
18
/7
1
(2
5.
3%
)
2/
20
(1
0%
)
16
/5
1
(3
1%
)
N
S
8/
69
(1
1.
5%
)
1/
18
(5
.5
5%
)
7/
51
(1
3.
7%
)
N
S
H
ig
h
LD
H
60
/1
33
(4
5%
)
13
/3
5
(3
7%
)
47
/9
8
(4
8%
)
N
S
41
/7
0
(5
8.
5%
)
12
/2
0
(6
0%
)
29
/4
9
(5
9%
)
N
S
19
/6
3
(3
0.
1%
)
1/
15
(6
.6
6%
)
18
/4
8
(3
7.
5%
)
0.
01
B
u
lk
y
71
/1
37
(5
2%
)
21
/3
8
(5
5%
)
50
/9
9
(5
1%
)
N
S
38
/6
8
(5
5.
8%
)
12
/2
0
(6
0%
)
26
/4
8
(5
4%
)
N
S
33
/6
9
(4
7.
8%
)
9/
18
(5
0%
)
24
/5
1
(4
7%
)
N
S
Ex
tr
an
o
d
al
si
te
s
⩾
2
43
/1
40
(3
0%
)
10
/3
8
(2
6%
)
33
/1
02
(3
2%
)
N
S
25
/7
1
(3
5%
)
6/
20
(3
0%
)
19
/5
1
(3
7%
)
N
S
18
/6
9
(2
6%
)
4/
18
(2
2.
2%
)
14
/5
1
(2
7.
4%
)
N
S
IP
I⩾
2
96
/1
39
(7
0%
)
22
/3
8
(5
9%
)
74
/1
01
(7
3%
)
N
S
59
/7
0
(8
4%
)
15
/2
0
(6
0%
)
44
/5
0
(8
8%
)
N
S
37
/6
9
(5
3%
)
7/
18
(4
0%
)
30
/5
1
(5
9%
)
N
S
A
SC
T
p
er
fo
rm
ed
82
/1
40
(5
9%
)
20
/3
8
(5
3%
)
62
/1
02
(6
1%
)
N
S
55
/7
1
(7
7%
)
14
/2
0
(7
0%
)
41
/5
1
(8
0%
)
N
S
27
/6
9
(3
9%
)
6/
18
(3
3.
3%
)
21
/5
1
(4
1%
)
N
S
Co
nd
iti
on
in
g
C
T
63
/8
2
(7
7%
)
17
/2
0
(8
5%
)
46
/6
2
(7
4%
)
N
S
39
/5
5
(7
0.
9%
)
12
/1
4
(8
5.
7%
)
27
/4
1
(6
6%
)
N
S
23
/2
7
(8
5%
)
5/
6
(8
3%
)
18
/2
1
(8
6%
)
N
S
H
D
-Z
ev
al
in
19
/8
2
(2
3%
)
3/
20
(1
5%
)
16
/6
2
(2
5%
)
N
S
16
/5
5
(2
9%
)
2/
14
(1
4.
2%
)
14
/4
1
(3
4%
)
N
S
4/
27
(1
5%
)
1/
6
(1
7%
)
3/
21
(1
4%
)
N
S
St
at
us
pr
e
A
SC
T
C
o
m
p
le
te
re
m
is
si
o
n
68
/8
2
(8
3%
)
16
/2
0
(8
0%
)
52
/6
2
(8
4%
)
N
S
46
/5
5
(8
4%
)
11
/1
4
(7
8%
)
34
/4
1
(8
3%
)
N
S
22
/2
7
(8
1%
)
5/
6
(8
3%
)
17
/2
1
(8
1%
)
N
S
Pa
rt
ia
l
re
m
is
si
o
n
12
/8
2
(1
5%
)
3/
20
(1
5%
)
10
/6
2
(1
6%
)
N
S
8/
55
(1
5%
)
2/
14
(1
4%
)
7/
41
(1
7%
)
N
S
4/
27
(1
5%
)
1/
6
(1
7%
)
3/
21
(1
4%
)
N
S
St
ab
le
d
is
ea
se
2/
82
(2
%
)
1/
20
(5
%
)
0
N
S
1/
55
(2
%
)
1/
14
(7
%
)
0
N
S
1/
27
(4
%
)
0
1/
21
(5
%
)
N
S
Re
as
on
fo
r
no
A
SC
T
D
is
ea
se
47
/5
8
(8
1%
)
16
/1
8
(8
0%
)
31
/4
0
(7
7%
)
N
S
12
/1
6
(8
7.
5%
)
6/
6
(1
00
%
)
6/
10
(6
0%
)
N
S
34
/4
2
(8
1%
)
10
/1
2
(8
3%
)
24
/3
0
(8
0%
)
N
S
Po
o
r
m
o
b
ili
ze
r
3/
58
(5
.5
%
)
1/
18
(1
1.
1%
)
2/
40
(5
%
)
N
S
0/
16
(0
%
)
0/
0
(%
)
0
(0
%
)
N
S
3/
42
(7
%
)
1/
12
(8
.3
%
)
2/
30
(6
%
)
N
S
A
d
ve
rs
e
ev
en
t
7/
58
(1
2%
)
1/
18
(1
3.
3%
)
6/
40
(1
5.
5%
)
N
S
4/
16
(2
5%
)
0/
6
(0
%
)
4/
10
(4
0%
)
N
S
4/
42
(9
.5
%
)
1/
12
(8
.3
%
)
3/
30
(1
0%
)
N
S
O
th
er
1/
58
(1
.5
%
)
0
1/
40
(2
.5
%
)
N
S
–
–
–
–
1/
42
(2
.4
%
)
0/
0
(0
%
)
1/
30
(4
%
)
N
S
M
YC
4
40
%
65
/1
40
(4
6%
)
38
/3
8
(1
00
%
)
27
/1
02
(2
6%
)
0.
00
3
31
/7
1
(4
3.
6%
)
20
/2
0
(1
00
%
)
11
/5
1
(2
1%
)
o
0.
00
01
34
/6
9
(4
9.
2%
)
18
/1
8
(1
00
%
)
16
/5
1
(3
1.
3%
)
o
0.
00
01
B
C
L2
4
70
%
78
/1
40
(5
5%
)
38
/3
8
(1
00
%
)
40
/1
02
(3
9%
)
o
0.
00
01
37
/7
1
(5
2.
1%
)
20
/2
0
(1
00
%
)
17
/5
1
(3
3%
)
o
0.
00
01
41
/6
9
(5
9.
4%
)
18
/1
8
(1
00
%
)
23
/5
1
(4
5%
)
o
0.
00
01
M
YC
/
B
C
L2
co
-e
xp
re
ss
io
n
38
/1
40
(2
7%
)
38
/3
8
(1
00
%
)
0/
10
2
(0
%
)
o
0.
00
01
20
/7
1
(2
8.
1%
)
20
/2
0
(1
00
%
)
0/
51
(0
%
)
o
0.
00
01
18
/6
9
(2
6%
)
18
/1
8
(1
00
%
)
0/
51
(0
%
)
o
0.
00
01
A
B
C
-D
LB
C
L
71
/1
16
(6
1%
)
22
/2
9
(7
6%
)
59
/8
7
(6
9%
)
N
S
43
/5
9
(7
3%
)
11
/1
4
(7
8%
)
32
/4
5
(7
1.
1%
)
N
S
34
/6
1
(5
6%
)
13
/1
8
(7
2%
)
21
/4
3
(4
9%
)
N
S
K
i-6
7
H
ig
h
90
/1
28
(7
0%
)
27
/3
5
(7
7%
)
63
/9
3
(8
7%
)
N
S
40
/5
7
(7
0%
)
14
/1
7
(8
2%
)
26
/4
0
(6
5%
)
N
S
44
/6
6
(6
6%
)
11
/1
5
(7
3%
)
33
/5
1
(6
5%
)
N
S
A
b
b
re
vi
at
io
n
s:
A
SC
T,
au
to
lo
g
o
u
s
st
em
ce
ll
tr
an
sp
la
n
t;
LD
H
,
la
ct
at
e
d
eh
yd
ro
g
en
as
e;
N
S,
n
o
n
si
g
n
iﬁ
ca
n
t.
Letter to the Editor
2
Blood Cancer Journal
salvage high-dose therapy and 27 (90%) were transplanted.
Aberrant expression of MYC and BCL2 by IHC was observed in 34
(49%) and 41 (59%) patients, respectively. Among them, 18 (26%)
were characterized by BCL2 and MYC co-expression. Overall the
relapsed cohort 5-year EFS and OS were 28.8% (95% CI, 21.9–
33.7%) and 39.6% (95% CI, 32.6–46.6%), respectively. Patients
relapsed within 1 year from ﬁrst line were associated with a
signiﬁcantly worse outcome in terms of 5-year EFS (15.5% (95% IC
9.9–21.1%) vs 62.2% (95% IC, 49.6–74.8%); P= 0.0008) and OS
(24.3% (95% IC 17–31.6%) vs 73.6% (95% IC, 69.6–87.6%);
P= 0.001; Supplementary Figure S2). This results conﬁrmed what
previously described by CORAL trial, and suggest that standard
high-dose salvage therapies may be ineffective among early
relapsed patients.10 The only other variable associated with
inferior outcome at ﬁrst relapse in terms of EFS and OS was the
extranodal involvement of ⩾ 2 sites (P= 0.01 and P= 0.002,
respectively). High lactate dehydrogenase (LDH) levels were asso-
ciated with inferior EFS but not OS. Conversely, ECOG score ⩾2 and
presence of bulky were associated with reduced survival (P=0.02 and
P= 0.04, respectively). All tested IHC markers did not have any
Figure 1. Kaplan–Meier estimated curves of EFS (a, c, e) and OS (b, d, f) according to MYC/BCL2 co-expression considering all (a, b), naïve (c, d)
and relapsed/refractory (e, f) DLBCL patients.
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clinical prognostication in terms of OS and EFS. Speciﬁcally,
double expressor patients did not show any signiﬁcant difference
as compared with other patients in terms of 5-year EFS (37.5%
(95% IC, 25.8–49.2%) vs 27.5% (95% IC, 21–34%), P= 0.5) and
5-year OS (20.5% (95% IC, 4.6–36.4%) vs 39.4% (95% IC, 31.2–47.6%),
P=0.8) (Figures 1e and f). In multivariate analysis, relapse in the
1 year after ﬁrst-line therapy was the only variable that retained its
independence for EFS and OS (Supplementary Table S4).
Overall, results of this study suggest that standard high-dose
therapy and ﬁnal transplant consolidation may abolish the poor
prognostic value associated with MYC/BCL2 co-expression among
young and/or ﬁt DLBCL patients both in ﬁrst line and ﬁrst relapse.
As expected the clinical outcome of transplanted and no
transplanted patients was signiﬁcantly different, but this was not
inﬂuenced by MYC/BCL2 co-expression (Supplementary Figure S3).
This suggests that MYC/BCL2 co-expression is not directly involved
in refractoriness and resistance to intensive salvage therapy
Although the cutoff of ⩾ 40% for MYC positivity in IHC is widely
accepted,14 different BCL2 cutoffs were used to deﬁne double
expressor patients.1,4 For this reason, all analyses described above
were repeated using the alternative BCL2 cutoff described by
Johnson et al. (⩾50%),4 and all results were conﬁrmed (data not
shown).
In our series we found a signiﬁcant lower prevalence of double
hit DLBCL patients compared with other series.1–5,7,12 This
discrepancy could be due to the limited series size and to the
known low prevalence of double hit DLBCL among young
patients.1,3,4,12,15 For this reason our ﬁndings are not applicable
on this distinct and aggressive biological entity.
Future incorporation of novel agents into ﬁrst-line regimens
may improve the efﬁcacy and safety of intense chemotherapy
regimens such as R-HDS program, therefore improving the ﬁnal
outcome.
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